Join the VISIONaerieS.

Inspiration, imagination, and innovation. We share this passion for finding new approaches to protecting vision. United by great science, deep clinical insight, and a singular focus on your ophthalmic needs, we see the possibilities ahead and invite you to join us in creating the future of eye care.

Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialisation of first-in-class therapies for the treatment of glaucoma and other diseases of the eye.
See the future of eye care with Aerie.

Aerie Pharmaceuticals Jobs: 4

Date Job Title Location Salary  
24/02/2017 Technical Services & Process Manager Westmeath, Galway, Roscommon Negotiable More Details
22/02/2017 Manufacturing Director - Midlands Westmeath, Offaly Negotiable More Details
26/01/2017 Quality Assurance Director Roscommon, Westmeath, Galway Negotiable More Details
23/01/2017 Executive Assistant - Permanent role - €50,000 Dublin West, Westmeath, Kildare Negotiable More Details

Our Strategy:

  • The first new mechanisms of action (MOA) in a generation to treat patients with glaucoma, the largest prescription market in ophthalmology.

  • Designed to reduce elevated intraocular pressure (IOP), the cause of vision loss in open-angle glaucoma.

  • Two late development-stage products – Rhopressa™ (netarsudil ophthalmic solution) 0.02% and Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%.

  • Both products are eye drops taken once a day in the evening.

  • Each product has multiple mechanisms of action, including the novel targeting of the diseased tissue, or main drain in the eye – the source of elevated IOP; potential for disease modification.

  • Blockbuster revenue potential in a current $4.7 billion market in the US, Europe and Japan, which is expected to grow to more than $8 billion by 2023.

  • All products fully owned by Aerie with patents through to at least 2030.                   

More on Aerie's Strategy and Products >

Aerie Athlone:

Aerie currently employs 100 people located in Irvine - CA, Bedminster - NJ, Raleigh/Durham - NC, Dublin & Malta, with plans to expand to 160 by the end of 2017. We are building a broader organisation to prepare for our commercial launch and Athlone will be Aerie’s first manufacturing facility.

Following a €40m initial investment, Aerie acquired a 2,650m2 IDA Advanced Technology Building in Athlone to enable fast track start-up of operations. The site is being developed with a view to In-house commercial supply in 2020 and is a Drug Product facility end to end - Compunding to sterile filling to packaging with support capabilities like QC labs, warehousing etc.

Our Core Values:


Back to Top